Edward Morrow Atkinson III - 06 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Technical Ops. Off.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
06 Feb 2024
Net transactions value
$0
Form type
4
Filing time
08 Feb 2024, 16:24:55 UTC
Previous filing
05 Feb 2024
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +2,326 +17% $0.000000 16,205 06 Feb 2024 Direct F1
transaction VRTX Common Stock Award $0 +3,934 +24% $0.000000 20,139 06 Feb 2024 Direct F2
transaction VRTX Common Stock Award $0 +4,743 +24% $0.000000 24,882 07 Feb 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.
F3 Restricted stock unit award that vests in installments beginning on 02/17/2025.